These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 14652229)

  • 1. Critics question price of success in halted clinical trial of aromatase inhibitor letrozole.
    Twombly R
    J Natl Cancer Inst; 2003 Dec; 95(23):1738-9. PubMed ID: 14652229
    [No Abstract]   [Full Text] [Related]  

  • 2. [Endocrine therapy of causation: role of aromatase inhibitors in breast cancer].
    Longo F; Mansueto G
    Tumori; 2003; 89(6):21-8. PubMed ID: 14870836
    [No Abstract]   [Full Text] [Related]  

  • 3. Anti-tumor effects of letrozole.
    Miller WR; Anderson TJ; Dixon JM
    Cancer Invest; 2002; 20 Suppl 2():15-21. PubMed ID: 12442345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The ATAC study on adjuvants in breast cancer].
    Bravi S
    Suppl Tumori; 2004; 3(4):S15. PubMed ID: 15206200
    [No Abstract]   [Full Text] [Related]  

  • 5. [The ATAC study on adjuvants in breast cancer. What kind of repercussions will it have on clinical practice?].
    Gamucci T
    Suppl Tumori; 2004; 3(4):S16. PubMed ID: 15206201
    [No Abstract]   [Full Text] [Related]  

  • 6. [The optimal duration of adjuvant therapy in breast cancer: what kind of evidence? Hormone therapy: what kind of evidence?].
    Angiolini C
    Suppl Tumori; 2004; 3(4):S75-6. PubMed ID: 15206219
    [No Abstract]   [Full Text] [Related]  

  • 7. Long-term risk of breast cancer recurrence: the need for extended adjuvant therapy.
    Kaufmann M; Rody A
    J Cancer Res Clin Oncol; 2005 Aug; 131(8):487-94. PubMed ID: 15915367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1-98 letrozole trial.
    Forbes JF
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S2-7. PubMed ID: 16730270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Letrozole in breast cancer.
    Harris SR
    N Engl J Med; 2004 Feb; 350(7):727-30; author reply 727-30. PubMed ID: 14971059
    [No Abstract]   [Full Text] [Related]  

  • 10. Letrozole in breast cancer.
    Shahab N
    N Engl J Med; 2004 Feb; 350(7):727-30; author reply 727-30. PubMed ID: 14971058
    [No Abstract]   [Full Text] [Related]  

  • 11. Benefit of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
    DeGrendele H
    Clin Breast Cancer; 2003 Dec; 4(5):311-2. PubMed ID: 14715105
    [No Abstract]   [Full Text] [Related]  

  • 12. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
    Goss PE; Ingle JN; Martino S; Robert NJ; Muss HB; Piccart MJ; Castiglione M; Tu D; Shepherd LE; Pritchard KI; Livingston RB; Davidson NE; Norton L; Perez EA; Abrams JS; Therasse P; Palmer MJ; Pater JL
    N Engl J Med; 2003 Nov; 349(19):1793-802. PubMed ID: 14551341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The optimal duration of adjuvant therapy in breast cancer: what kind of evidence? Hormone therapy: the example of clinical studies].
    Giannessi PG
    Suppl Tumori; 2004; 3(4):S73-4. PubMed ID: 15206218
    [No Abstract]   [Full Text] [Related]  

  • 14. Hormonal therapy in early and advanced breast cancer.
    Buzdar AU
    Breast J; 2004; 10 Suppl 1():S19-21. PubMed ID: 14984485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Re: Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.
    Vakaet L
    J Natl Cancer Inst; 2006 Aug; 98(16):1162; author reply 1162-3. PubMed ID: 16912269
    [No Abstract]   [Full Text] [Related]  

  • 16. Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial.
    Goss PE
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S8-12. PubMed ID: 16730271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Letrozole after tamoxifen for breast cancer--what is the price of success?
    Bryant J; Wolmark N
    N Engl J Med; 2003 Nov; 349(19):1855-7. PubMed ID: 14551339
    [No Abstract]   [Full Text] [Related]  

  • 18. Letrozole versus tamoxifen in the treatment of advanced breast cancer and as neoadjuvant therapy.
    Smith IE
    J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):289-93. PubMed ID: 14623523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen.
    Mann BS; Johnson JR; Kelly R; Sridhara R; Williams G; Pazdur R
    Clin Cancer Res; 2005 Aug; 11(16):5671-7. PubMed ID: 16115902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
    Rasmussen BB; Regan MM; Lykkesfeldt AE; Dell'Orto P; Del Curto B; Henriksen KL; Mastropasqua MG; Price KN; Méry E; Lacroix-Triki M; Braye S; Altermatt HJ; Gelber RD; Castiglione-Gertsch M; Goldhirsch A; Gusterson BA; Thürlimann B; Coates AS; Viale G;
    Lancet Oncol; 2008 Jan; 9(1):23-8. PubMed ID: 18083065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.